Just 61% of hospitals surveyed evaluated models for accuracy on their own data, and less than half evaluated the models for ...

Johnson & Johnson MedTech (NYSE: JNJ) announced that it received CE mark approval for its dual-energy ThermoCool SmartTouch ...

Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for ...

The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.

Johnson & Johnson halted the limited rollout of its Varipulse pulsed field ablation system on Jan. 5 to “investigate the root causes of four reported neurovascular events in the U.S. external ...

Johnson & Johnson pauses U.S. Varipulse cases to investigate neurovascular events. The FDA-approved device integrates PFA ...

The FDA and European Medicines Agency (EMA) have granted several key designations to nipocalimab including: U.S. FDA Fast Track designation in hemolytic disease of the fetus and newborn (HDFN) and ...

Mendaera has found a leader with deep medical robotics experience to lead its commercialization push. Eric Davidson has taken ...

Onera Health, a leader in transforming sleep diagnostics and monitoring, is excited to announce the appointment of Maria ...

Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad ...

J&J's MedTech unit pauses all cases of the Varipulse PFA system as part of an external evaluation. Stock dips.

Johnson & Johnson has won Food and Drug Administration priority review for its application seeking approval of nipocalimab in certain patients with generalized myasthenia gravis.